42 related articles for article (PubMed ID: 28384413)
1. Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.
van den Born JC; Meziyerh S; Vart P; Bakker SJL; Berger SP; Florquin S; de Fijter JW; Gomes-Neto AW; Idu MM; Pol RA; Roelen DL; van Sandwijk MS; de Vries DK; de Vries APJ; Bemelman FJ; Sanders JSF
Transplantation; 2024 Feb; 108(2):556-566. PubMed ID: 37650722
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression Regimen Use and Outcomes in Older and Younger Adult Kidney Transplant Recipients: A National Registry Analysis.
Lentine KL; Cheungpasitporn W; Xiao H; McAdams-DeMarco M; Lam NN; Segev DL; Bae S; Ahn JB; Hess GP; Caliskan Y; Randall HB; Kasiske BL; Schnitzler MA; Axelrod DA
Transplantation; 2021 Aug; 105(8):1840-1849. PubMed ID: 33214534
[TBL] [Abstract][Full Text] [Related]
3. Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients.
Mitsuke A; Ohbo T; Arima J; Osako Y; Sakaguchi T; Matsushita R; Yoshino H; Tatarano S; Yamada Y; Sasaki H; Tanabe T; Fukuzawa N; Tanaka H; Nishio Y; Hideki E; Harada H
PLoS One; 2023; 18(10):e0287059. PubMed ID: 37819994
[TBL] [Abstract][Full Text] [Related]
4. Early Steroid Withdrawal in Black Transplant Patients: A Selective Process.
Augustine JJ
Clin J Am Soc Nephrol; 2017 Jan; 12(1):7-9. PubMed ID: 27979978
[No Abstract] [Full Text] [Related]
5. Efficacy of Prednisone Avoidance in Patients With Liver Transplant Using the U.S. Food and Drug Administration Adverse Event Reporting System.
Ogura T; Shiraishi C
Cureus; 2024 May; 16(5):e60193. PubMed ID: 38868240
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation.
de Graav GN; Baan CC; Clahsen-van Groningen MC; Kraaijeveld R; Dieterich M; Verschoor W; von der Thusen JH; Roelen DL; Cadogan M; van de Wetering J; van Rosmalen J; Weimar W; Hesselink DA
Transplantation; 2017 Oct; 101(10):2571-2581. PubMed ID: 28403127
[TBL] [Abstract][Full Text] [Related]
7. Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center.
Jeong HJ; Ahn YH; Park E; Choi Y; Yi NJ; Ko JS; Min SI; Ha JW; Ha IS; Cheong HI; Kang HG
Korean J Pediatr; 2017 Mar; 60(3):86-93. PubMed ID: 28392824
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients.
Woillard JB; Debord J; Monchaud C; Saint-Marcoux F; Marquet P
Clin Pharmacokinet; 2017 Dec; 56(12):1491-1498. PubMed ID: 28389935
[TBL] [Abstract][Full Text] [Related]
9. Safety and metabolic advantages of steroid withdrawal after 6 months posttransplant in de novo kidney transplantation: A 1-year prospective cohort study.
Bang JB; Oh CK; Kim YS; Kim SH; Yu HC; Kim CD; Ju MK; So BJ; Lee SH; Han SY; Jung CW; Kim JK; Ahn HJ; Lee SH; Jeon JY
Immun Inflamm Dis; 2022 Mar; 10(3):e576. PubMed ID: 34913271
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study.
Alghanem SS; Soliman MM; Alibrahim AA; Gheith O; Kenawy AS; Awad A
Front Pharmacol; 2020; 11():566638. PubMed ID: 33658922
[No Abstract] [Full Text] [Related]
11. The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States.
Incerti D; Summers N; Ton TGN; Boscoe A; Chandraker A; Stevens W
MDM Policy Pract; 2018; 3(1):2381468318781811. PubMed ID: 30288451
[No Abstract] [Full Text] [Related]
12. Steroid avoidance or withdrawal for kidney transplant recipients.
Pascual J; Zamora J; Galeano C; Royuela A; Quereda C
Cochrane Database Syst Rev; 2009 Jan; (1):CD005632. PubMed ID: 19160257
[TBL] [Abstract][Full Text] [Related]
13. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
[TBL] [Abstract][Full Text] [Related]
14. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study.
Gheith OA; Nematalla AH; Bakr MA; Refaie A; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2011 Apr; 9(2):121-7. PubMed ID: 21453230
[TBL] [Abstract][Full Text] [Related]
15. A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients.
Taber DJ; Hunt KJ; Gebregziabher M; Srinivas T; Chavin KD; Baliga PK; Egede LE
Clin J Am Soc Nephrol; 2017 Jan; 12(1):131-139. PubMed ID: 27979979
[TBL] [Abstract][Full Text] [Related]
16. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Tacrolimus-Based Steroid Sparing versus Steroid Maintenance Regimens in Kidney Transplantation: Results from Discrete Event Simulation.
Desai VCA; Ferrand Y; Cavanaugh TM; Kelton CML; Caro JJ; Goebel J; Heaton PC
Med Decis Making; 2017 Oct; 37(7):827-843. PubMed ID: 28384413
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
